StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Monday. The firm issued a sell rating on the stock.

Tonix Pharmaceuticals Trading Down 3.6 %

Shares of NASDAQ TNXP opened at $11.94 on Monday. Tonix Pharmaceuticals has a 1 year low of $10.82 and a 1 year high of $1,248.00. The stock has a market cap of $22.33 million, a P/E ratio of 0.00 and a beta of 2.07. The firm has a 50-day moving average of $29.49 and a 200 day moving average of $25.62. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($203.00) by $180.00. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, sell-side analysts expect that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 120,292 shares of the company’s stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned 6.43% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.